{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:03:39Z","timestamp":1791241419897,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["847740, 863620"],"award-info":[{"award-number":["847740, 863620"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT94252310158"],"award-info":[{"award-number":["HT94252310158"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-00998-1","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:00:51Z","timestamp":1752516051000},"page":"239-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular risks in men with prostate cancer: a pragmatic, clinician-oriented review of risk stratification and management strategies"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1271-0531","authenticated-orcid":false,"given":"Aditya","family":"Bhave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-7956","authenticated-orcid":false,"given":"Harikrishnan","family":"Hyma Kunhiraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4584-3308","authenticated-orcid":false,"given":"Tarek","family":"Nahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-9068","authenticated-orcid":false,"given":"Omar","family":"Makram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-0779","authenticated-orcid":false,"given":"Priyanshu","family":"Nain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-2096","authenticated-orcid":false,"given":"Sagar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashanda","family":"Esdaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-7270","authenticated-orcid":false,"given":"Martha","family":"Terris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1174","authenticated-orcid":false,"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"998_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"998_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"key":"998_CR3","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto A, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"998_CR4","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. Accessed February 23, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"998_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547\u201358.","journal-title":"N Engl J Med"},{"key":"998_CR6","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/cancers14174149","volume":"14","author":"R Clark","year":"2022","unstructured":"Clark R, Vesprini D, Narod SA. The effect of age on prostate cancer survival. Cancers (Basel). 2022;14:4149. https:\/\/doi.org\/10.3390\/cancers14174149.","journal-title":"Cancers (Basel)"},{"key":"998_CR7","doi-asserted-by":"publisher","first-page":"e390166","DOI":"10.1200\/EDBK_390166","volume":"43","author":"AA Hamid","year":"2023","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"998_CR8","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"998_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/cncr.33584","volume":"127","author":"AB Weiner","year":"2021","unstructured":"Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: a contemporary, US population-based analysis. Cancer. 2021;127:2895\u2013904. https:\/\/doi.org\/10.1002\/cncr.33584.","journal-title":"Cancer"},{"key":"998_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","volume":"6","author":"DP Leong","year":"2024","unstructured":"Leong DP, Guha A, Morgans AK, Niazi T, Pinthus JH. Cardiovascular risk in prostate cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6:835\u201346. https:\/\/doi.org\/10.1016\/j.jaccao.2024.09.012.","journal-title":"JACC CardioOncol"},{"key":"998_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccl.2024.09.003","volume":"43","author":"DP Leong","year":"2025","unstructured":"Leong DP, Cirne F, Pinthus JH. Cardiovascular risk in prostate cancer. Cardiol Clin. 2025;43:83\u201391. https:\/\/doi.org\/10.1016\/j.ccl.2024.09.003.","journal-title":"Cardiol Clin"},{"key":"998_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","volume":"5","author":"H Klimis","year":"2023","unstructured":"Klimis H, Pinthus JH, Aghel N, Duceppe E, Fradet V, Brown I, et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol. 2023;5:70\u201381. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.008.","journal-title":"JACC CardioOncol"},{"key":"998_CR13","doi-asserted-by":"publisher","first-page":"1130691","DOI":"10.3389\/fcvm.2023.1130691","volume":"10","author":"Z Luo","year":"2023","unstructured":"Luo Z, Chi K, Zhao H, Liu L, Yang W, Luo Z, et al. Cardiovascular mortality by cancer risk stratification in patients with localized prostate cancer: a SEER-based study. Front Cardiovasc Med. 2023;10:1130691.","journal-title":"Front Cardiovasc Med"},{"key":"998_CR14","first-page":"1","volume":"2022","author":"P Davey","year":"2022","unstructured":"Davey P, Alexandrou K. Assessment and mitigation of cardiovascular risk for prostate cancer patients: a review of the evidence. Int J Clin Pr. 2022;2022:1\u201313.","journal-title":"Int J Clin Pr"},{"key":"998_CR15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","unstructured":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439\u201354.","journal-title":"Eur Heart J"},{"key":"998_CR16","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","volume":"42","author":"SCORE2-OP Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","unstructured":"SCORE2-OP Working Group and ESC Cardiovascular Risk Collaboration, et al. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42:2455\u201367.","journal-title":"Eur Heart J"},{"key":"998_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jama.2018.8359","volume":"320","author":"US Preventive Services Task Force","year":"2018","unstructured":"US Preventive Services Task Force. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:272\u201381.","journal-title":"JAMA"},{"key":"998_CR18","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099.","journal-title":"BMJ"},{"key":"998_CR19","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","volume":"73","author":"DM Lloyd-Jones","year":"2019","unstructured":"Lloyd-Jones DM, Braun LT, Ndumele CE, Smith JrSC, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2019;73:3153\u201367.","journal-title":"J Am Coll Cardiol"},{"key":"998_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement. Eur J Heart Fail. 2020;22:1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920.","journal-title":"Eur J Heart Fail"},{"key":"998_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans A, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation. 2016;133:537\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.012519.","journal-title":"Circulation"},{"key":"998_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11886-023-01909-3","volume":"25","author":"CT Ng","year":"2023","unstructured":"Ng CT, Bonilla HMG, Bryce AH, Singh P, Herrmann J. Approaches to prevent and manage cardiovascular disease in patients receiving therapy for prostate cancer. Curr Cardiol Rep. 2023;25:889\u201399.","journal-title":"Curr Cardiol Rep"},{"key":"998_CR23","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188\u201394. https:\/\/doi.org\/10.1002\/cncr.23440.","journal-title":"Cancer"},{"key":"998_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.juro.2014.12.027","volume":"193","author":"HT Tsai","year":"2015","unstructured":"Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Yood MU, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015;193:1956\u201362. https:\/\/doi.org\/10.1016\/j.juro.2014.12.027.","journal-title":"J Urol"},{"key":"998_CR25","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s11096-020-01143-9","volume":"42","author":"YH Wu","year":"2020","unstructured":"Wu YH, Jhan JH, Ke HL, Tseng SI, Chang YH, Yeh HC, et al. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study. Int J Clin Pharm. 2020;42:1433\u20139. https:\/\/doi.org\/10.1007\/s11096-020-01143-9.","journal-title":"Int J Clin Pharm"},{"key":"998_CR26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00520-015-3016-y","volume":"24","author":"BD Gonzalez","year":"2016","unstructured":"Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, et al. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016;24:2201\u20137. https:\/\/doi.org\/10.1007\/s00520-015-3016-y.","journal-title":"Support Care Cancer"},{"key":"998_CR27","doi-asserted-by":"publisher","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9:e107516. https:\/\/doi.org\/10.1371\/journal.pone.0107516.","journal-title":"PLoS One"},{"key":"998_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A. Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10:874\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549.","journal-title":"JAMA Oncol"},{"key":"998_CR29","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1200\/JCO.2025.43.16_suppl.5041","volume":"43","author":"A Bryce","year":"2025","unstructured":"Bryce A, Touya M, Nimke D, Young C, Shao S, Rozario N, et al. Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US). JCO. 2025;43:5041\u20135041. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5041.","journal-title":"JCO"},{"key":"998_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","volume":"24","author":"HY Lee","year":"2021","unstructured":"Lee HY, Chen HL, Teoh JY, Chen TC, Hao SY, Tsai HY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021;24:244\u201352. https:\/\/doi.org\/10.1038\/s41391-020-00275-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"998_CR31","doi-asserted-by":"publisher","first-page":"1220305","DOI":"10.3389\/fonc.2023.1220305","volume":"13","author":"E Ramos-Ruperez","year":"2023","unstructured":"Ramos-Ruperez E, Escudero-Vilaplana V, Ruiz-Briones P, Collado-Borrell R, Villanueva-Bueno C, Revuelta-Herrero JL, et al. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy. Front Oncol. 2023;13:1220305. https:\/\/doi.org\/10.3389\/fonc.2023.1220305.","journal-title":"Front Oncol"},{"key":"998_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40959-021-00090-2","volume":"7","author":"R Araujo-Gutierrez","year":"2021","unstructured":"Araujo-Gutierrez R, Chitturi KR, Xu J, Wang Y, Kinder E, Senapati A, et al. Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardiooncology. 2021;7:4. https:\/\/doi.org\/10.1186\/s40959-021-00090-2.","journal-title":"Cardiooncology"},{"key":"998_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Br\u00f8nnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1209825.","journal-title":"N Engl J Med"},{"key":"998_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00018-018-2956-z","volume":"76","author":"B Baselet","year":"2019","unstructured":"Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699\u2013728. https:\/\/doi.org\/10.1007\/s00018-018-2956-z.","journal-title":"Cell Mol Life Sci"},{"key":"998_CR35","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/gerona\/glq113","volume":"65","author":"Z Ungvari","year":"2010","unstructured":"Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65:1028\u201341. https:\/\/doi.org\/10.1093\/gerona\/glq113.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"998_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/jrr\/rrw064","volume":"57","author":"S Tapio","year":"2016","unstructured":"Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016;57:439\u201348.","journal-title":"J Radiat Res"},{"key":"998_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/pros.23967","volume":"80","author":"ND Shore","year":"2020","unstructured":"Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate. 2020;80:527\u201344. https:\/\/doi.org\/10.1002\/pros.23967.","journal-title":"Prostate"},{"key":"998_CR38","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","volume":"25","author":"AV D\u2019Amico","year":"2007","unstructured":"D\u2019Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420\u20135. https:\/\/doi.org\/10.1200\/JCO.2006.09.3369.","journal-title":"J Clin Oncol"},{"key":"998_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14779072.2018.1538785","volume":"16","author":"JR Niska","year":"2018","unstructured":"Niska JR, Thorpe CS, Allen SM, Daniels TB, Rule WG, Schild SE, et al. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Expert Rev Cardiovasc Ther. 2018;16:931\u201350. https:\/\/doi.org\/10.1080\/14779072.2018.1538785.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"998_CR40","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.juro.2014.11.006","volume":"193","author":"AK Morgans","year":"2015","unstructured":"Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol. 2015;193:1226\u201331. https:\/\/doi.org\/10.1016\/j.juro.2014.11.006.","journal-title":"J Urol"},{"key":"998_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jama.299.3.289","volume":"299","author":"AV D\u2019Amico","year":"2008","unstructured":"D\u2019Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289\u201395.","journal-title":"JAMA"},{"key":"998_CR42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jama.2015.8577","volume":"314","author":"AV D\u2019Amico","year":"2015","unstructured":"D\u2019Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Long-term follow up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314:1291\u20133.","journal-title":"JAMA"},{"key":"998_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107\u201318.","journal-title":"N Engl J Med"},{"key":"998_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijrobp.2021.08.031","volume":"112","author":"CU Jones","year":"2022","unstructured":"Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, et al. Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: long-term update of the NRG\/RTOG 9408 randomized clinical trial. Int J Radiat Oncol Biol Phys. 2022;112:294\u2013303.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"998_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","volume":"3","author":"JD Mitchell","year":"2021","unstructured":"Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society. JACC CardioOncol. 2021;3:360\u201380. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.003.","journal-title":"JACC CardioOncol"},{"key":"998_CR46","first-page":"563","volume":"72","author":"JA Jurado","year":"2008","unstructured":"Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Inter. 2008;72:563\u20138.","journal-title":"Catheter Cardiovasc Inter"},{"key":"998_CR47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.pcd.2024.05.003","volume":"18","author":"Q Tu","year":"2024","unstructured":"Tu Q, Lin S, Hyun K, Hafiz N, Manandi D, Koh AS, et al. The effects of multidisciplinary collaborative care on cardiovascular risk factors among patients with diabetes in primary care settings: a systematic review and meta-analysis. Prim Care Diabetes. 2024;18:381\u201392. https:\/\/doi.org\/10.1016\/j.pcd.2024.05.003.","journal-title":"Prim Care Diabetes"},{"key":"998_CR48","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2020.12.031","volume":"79","author":"RJ Hamilton","year":"2021","unstructured":"Hamilton RJ, Ding K, Crook JM, O\u2019Callaghan CJ, Higano CS, Dearnaley DP, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. Eur Urol. 2021;79:446\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.031.","journal-title":"Eur Urol"},{"key":"998_CR49","doi-asserted-by":"publisher","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4:e210070. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0070.","journal-title":"JAMA Netw Open"},{"key":"998_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/CIRCULATIONAHA.124.065473","volume":"150","author":"JJ Moslehi","year":"2024","unstructured":"Moslehi JJ. Cardio-oncology: a new clinical frontier and novel platform for cardiovascular investigation. Circulation. 2024;150:513\u20135.","journal-title":"Circulation"},{"key":"998_CR51","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203:1109\u201316.","journal-title":"J Urol"},{"key":"998_CR52","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"998_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-024-00801-7","volume":"28","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Xiong X, Zheng Q, Deng Q, Hao Y, Liu D, et al. High-intensity interval training versus moderate-intensity continuous training for localized prostate cancer under active surveillance: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28:11\u201322. https:\/\/doi.org\/10.1038\/s41391-024-00801-7.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"998_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.56434\/j.arch.esp.urol.20247701.1","volume":"77","author":"M Sande-Rivadulla","year":"2024","unstructured":"Sande-Rivadulla M, Alonso-Calvete A, Soto-Gonz\u00e1lez M. Effects of muscle strength training in prostate cancer: a systematic review. Arch Esp Urol. 2024;77:1\u201315. https:\/\/doi.org\/10.56434\/j.arch.esp.urol.20247701.1.","journal-title":"Arch Esp Urol"},{"key":"998_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/EDE.0000000000001132","volume":"31","author":"CR Cardwell","year":"2020","unstructured":"Cardwell CR, O\u2019Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM, et al. The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies. Epidemiology. 2020;31:432\u201340.","journal-title":"Epidemiology"},{"key":"998_CR56","doi-asserted-by":"publisher","first-page":"1386597","DOI":"10.3389\/fonc.2024.1386597","volume":"14","author":"K Chen","year":"2024","unstructured":"Chen K, Wong TH, Tan YG, Tay KJ, Tan WC, Chan J, et al. Cardio-oncology in advanced prostate cancer. Front Oncol. 2024;14:1386597 Published online June 14, 2024.","journal-title":"Front Oncol"},{"key":"998_CR57","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/cncr.35172","volume":"130","author":"S Loeb","year":"2024","unstructured":"Loeb S, Hua Q, Bauer SR, Kenfield SA, Morgans AK, Chan JM, et al. Plant-based diet associated with better quality of life in prostate cancer survivors. Cancer. 2024;130:1618\u201328. https:\/\/doi.org\/10.1002\/cncr.35172.","journal-title":"Cancer"},{"key":"998_CR58","doi-asserted-by":"publisher","first-page":"e249053","DOI":"10.1001\/jamanetworkopen.2024.9053","volume":"7","author":"VN Liu","year":"2024","unstructured":"Liu VN, Van Blarigan EL, Zhang L, Graff RE, Loeb S, Langlais CS, et al. Plant-based diets and disease progression in men with prostate cancer. JAMA Netw Open. 2024;7:e249053. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9053.","journal-title":"JAMA Netw Open"},{"key":"998_CR59","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/ije\/30.5.1119","volume":"30","author":"L Kilander","year":"2001","unstructured":"Kilander L, Berglund L, Boberg M, Vessby B, Lithell H. Education, lifestyle factors and mortality from cardiovascular disease and cancer: a 25-year follow-up of Swedish 50-year-old men. Int J Epidemiol. 2001;30:1119\u201326.","journal-title":"Int J Epidemiol"},{"key":"998_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10389-023-01825-4","volume":"32","author":"T Wang","year":"2024","unstructured":"Wang T, Li Y, Zheng X. Association of socioeconomic status with cardiovascular disease and cardiovascular risk factors: a systematic review and meta-analysis. J Public Health. 2024;32:385\u201399.","journal-title":"J Public Health"},{"key":"998_CR61","doi-asserted-by":"publisher","first-page":"e014629","DOI":"10.1161\/JAHA.119.014629","volume":"9","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liu B, Rong S, Du Y, Xu G, Snetselaar LG, et al. Food insecurity is associated with cardiovascular and all-cause mortality among adults in the United States. J Am Heart Assoc. 2020;9:e014629.","journal-title":"J Am Heart Assoc"},{"key":"998_CR62","doi-asserted-by":"publisher","first-page":"e025581","DOI":"10.1161\/JAHA.122.025581","volume":"12","author":"I Acquah","year":"2023","unstructured":"Acquah I, Hagan K, Javed Z, Taha MB, Valero-Elizondo J, Nwana N, et al. Social determinants of cardiovascular risk, subclinical cardiovascular disease, and cardiovascular events. J Am Heart Assoc. 2023;12:e025581. https:\/\/doi.org\/10.1161\/JAHA.122.025581.","journal-title":"J Am Heart Assoc"},{"key":"998_CR63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.14336\/AD.2014.0500346","volume":"5","author":"KL Saban","year":"2014","unstructured":"Saban KL, Mathews HL, DeVon HA, Janusek LW. Epigenetics and social context: implications for disparity in cardiovascular disease. Aging Dis. 2014;5:346\u201355. https:\/\/doi.org\/10.14336\/AD.2014.0500346.","journal-title":"Aging Dis"},{"key":"998_CR64","doi-asserted-by":"publisher","first-page":"e033295","DOI":"10.1161\/JAHA.123.033295","volume":"13","author":"N Stabellini","year":"2024","unstructured":"Stabellini N, Cullen J, Bittencourt MS, Moore JX, Sutton A, Nain P, et al. Allostatic load\/chronic stress and cardiovascular outcomes in patients diagnosed with breast, lung, or colorectal cancer. J Am Heart Assoc. 2024;13:e033295. https:\/\/doi.org\/10.1161\/JAHA.123.033295.","journal-title":"J Am Heart Assoc"},{"key":"998_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2024.42.4_suppl.263","volume":"42","author":"N Stabellini","year":"2024","unstructured":"Stabellini N, Cullen J, Bittencourt MS, Moore JX, Weintraub NL, Datta B, et al. Individual-level social determinants of health and allostatic load\/chronic toxic stress in men with prostate cancer. J Clin Oncol. 2024;42:263.","journal-title":"J Clin Oncol"},{"key":"998_CR66","unstructured":"National Association of Community Health Centers Inc, Association of Asian Pacific Community Health Organizations, Oregon Primary Care Association. PRAPARE: Protocol for Responding to and Assessing Patient Assets, Risks, and Experiences. 2016. Accessed February 27, 2025. https:\/\/www.nachc.org\/research-and-data\/prapare\/."},{"key":"998_CR67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/pop.2019.0158","volume":"23","author":"M Moen","year":"2020","unstructured":"Moen M, Storr C, German D, Friedmann E, Johantgen M. A review of tools to screen for social determinants of health in the United States: a practice brief. Popul Health Manag. 2020;23:422\u20139. https:\/\/doi.org\/10.1089\/pop.2019.0158.","journal-title":"Popul Health Manag"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00998-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00998-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00998-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:42:24Z","timestamp":1779331344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00998-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00998-1","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AG has consulted for Myovant, Novartis, and Pfizer, but has no conflict of interest associated with this work. None of the other authors have any conflicts of interest related to this work to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}